Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.385 USD | -3.00% | -4.47% | -12.48% |
16/05 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
29/04 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
End-of-day quotes
Sector Bio Therapeutic Drugs
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
1.96Cr | - | - | - | |||
12TCr | ||||||
11TCr | ||||||
2.34TCr | - | |||||
2.18TCr | - | |||||
1.81TCr |
- Stock Market
- Equities
- AIM Stock
- Charts AIM ImmunoTech Inc.
- Sector Chart